Minhtuan Nguyenhuy1, Yifan Xu2, Julian Maingard3, Stephen Barnett4,5, Hong Kuan Kok6, Mark Brooks7, Ashu Jhamb8, Hamed Asadi7, Simon Knight4,3. 1. Department of Thoracic Surgery, Western Hospital, Footscray, Melbourne, VIC, 3011, Australia. michaelnh1@gmail.com. 2. Department of Surgery, Peninsula Health, Frankston, VIC, 3199, Australia. 3. Department of Interventional Radiology, Monash Health, Clayton, VIC, 3168, Australia. 4. Department of Thoracic Surgery, Western Hospital, Footscray, Melbourne, VIC, 3011, Australia. 5. Department of Thoracic Surgery, Austin Health, Heidelberg, VIC, 3084, Australia. 6. Interventional Radiology Service, Northern Health Radiology, Epping, VIC, 3076, Australia. 7. Department of Interventional Radiology, Austin Health, Heidelberg, VIC, Australia. 8. Department of Vascular and Interventional Radiology, St Vincent's Hospital, Fiztroy, VIC, 3065, Australia.
Abstract
BACKGROUND: Pulmonary metastasectomy has been widely adopted in the treatment of metastatic disease. In recent years image guided ablation has seen increased use in the treatment of thoracic malignancies. The objective of this study was to evaluate oncological outcomes following percutaneous ablation (PA) of pulmonary metastasis. METHODS: A comprehensive search of the PubMed, MEDLINE and EMBASE databases from January 2000 to August 2021 was performed to identify studies evaluating patient survival following ablation of lung metastasis. Pooled outcomes have been presented with a random effects model to assess primary outcomes of overall survival, progression free survival and 1-year local control. Secondary outcomes included procedural mortality, major complications, and the incidence of pneumothorax. RESULTS: A total of 24 studies were identified. The pooled median overall survival was 5.13 [95% confidence interval (CI): 4.37-6.84] years, and the 1-, 3-, 5-year progression free survival rates were 53%, 26% and 20% respectively. The 1-year local control rate was 91% (95%CI: 86-95%). Periprocedural mortality was rare (0%; 95%CI: 0-1%), as were major complications excluding pneumothorax (1%; 95%CI: 1-2%). Pneumothorax developed in 44% of ablation sessions, although only half of these required chest tube placement. Most patients were able to be discharged day one post-procedurally. CONCLUSION: PA demonstrates high overall, progression free and local tumour survival in patients with lung metastasis. Complications and mortality are also rare. Consideration of its use should be made in a tumour board meeting in conjunction with surgical and radiotherapy perspectives for targeted local control of metastases.
BACKGROUND: Pulmonary metastasectomy has been widely adopted in the treatment of metastatic disease. In recent years image guided ablation has seen increased use in the treatment of thoracic malignancies. The objective of this study was to evaluate oncological outcomes following percutaneous ablation (PA) of pulmonary metastasis. METHODS: A comprehensive search of the PubMed, MEDLINE and EMBASE databases from January 2000 to August 2021 was performed to identify studies evaluating patient survival following ablation of lung metastasis. Pooled outcomes have been presented with a random effects model to assess primary outcomes of overall survival, progression free survival and 1-year local control. Secondary outcomes included procedural mortality, major complications, and the incidence of pneumothorax. RESULTS: A total of 24 studies were identified. The pooled median overall survival was 5.13 [95% confidence interval (CI): 4.37-6.84] years, and the 1-, 3-, 5-year progression free survival rates were 53%, 26% and 20% respectively. The 1-year local control rate was 91% (95%CI: 86-95%). Periprocedural mortality was rare (0%; 95%CI: 0-1%), as were major complications excluding pneumothorax (1%; 95%CI: 1-2%). Pneumothorax developed in 44% of ablation sessions, although only half of these required chest tube placement. Most patients were able to be discharged day one post-procedurally. CONCLUSION: PA demonstrates high overall, progression free and local tumour survival in patients with lung metastasis. Complications and mortality are also rare. Consideration of its use should be made in a tumour board meeting in conjunction with surgical and radiotherapy perspectives for targeted local control of metastases.
Authors: Christophe L Nguyen; Walter J Scott; Nancy A Young; Tina Rader; Lydia R Giles; Melvyn Goldberg Journal: Chest Date: 2005-11 Impact factor: 9.410
Authors: U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam Journal: J Thorac Cardiovasc Surg Date: 1997-01 Impact factor: 5.209
Authors: Riccardo Lencioni; Laura Crocetti; Roberto Cioni; Robert Suh; Derek Glenn; Daniele Regge; Thomas Helmberger; Alice R Gillams; Andrea Frilling; Marcello Ambrogi; Carlo Bartolozzi; Alfredo Mussi Journal: Lancet Oncol Date: 2008-06-17 Impact factor: 41.316
Authors: Kenneth R Hess; Gauri R Varadhachary; Sarah H Taylor; Wei Wei; Martin N Raber; Renato Lenzi; James L Abbruzzese Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934